Recursion announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractory B-cell lymphomas. EXCELERIZE, the Phase 1, open-label, multicenter dose-escalation study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of REC-3565 in two parts. Part A will assess monotherapy dosing to identify a recommended dose for combination in Part B, which will evaluate combination regimens to inform future studies in B-cell cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals
- Recursion Pharmaceuticals call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment buys 205K shares of Recursion Pharmaceuticals today
- Cathie Wood’s ARK Investment buys 161K shares of Recursion Pharmaceuticals today
- Recursion Pharmaceuticals Strengthens Board with New Appointments